deltorphin ii, ala(2)- has been researched along with yohimbine in 2 studies
| Studies (deltorphin ii, ala(2)-) | Trials (deltorphin ii, ala(2)-) | Recent Studies (post-2010) (deltorphin ii, ala(2)-) | Studies (yohimbine) | Trials (yohimbine) | Recent Studies (post-2010) (yohimbine) |
|---|---|---|---|---|---|
| 233 | 0 | 20 | 5,893 | 253 | 532 |
| Protein | Taxonomy | deltorphin ii, ala(2)- (IC50) | yohimbine (IC50) |
|---|---|---|---|
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.0353 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 1.02 | |
| D(2) dopamine receptor | Homo sapiens (human) | 2.06 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 1.3 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.0428 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0466 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.126 | |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0682 | |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0682 | |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0682 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 1.3 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 1.013 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.126 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.074 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 1.3 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 1.689 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Banfor, PN; Grabow, TS; Hammond, DL; Hurley, RW | 1 |
| Paul, D; Ware, TD | 1 |
2 other study(ies) available for deltorphin ii, ala(2)- and yohimbine
| Article | Year |
|---|---|
Supraspinal and spinal delta(2) opioid receptor-mediated antinociceptive synergy is mediated by spinal alpha(2) adrenoceptors.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Analgesics, Opioid; Anesthesia, Spinal; Animals; Dexmedetomidine; Drug Synergism; Injections, Spinal; Male; Nociceptors; Norepinephrine; Oligopeptides; Pain Measurement; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Receptors, Opioid, delta; Spinal Cord; Yohimbine | 1999 |
Cross-tolerance between analgesia produced by xylazine and selective opioid receptor subtype treatments.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adrenergic alpha-Agonists; Analgesia; Analgesics, Opioid; Animals; Dose-Response Relationship, Drug; Drug Tolerance; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalin, D-Penicillamine (2,5)-; Male; Mice; Oligopeptides; Receptors, Adrenergic, alpha-2; Xylazine; Yohimbine | 2000 |